Psyence Biomedical shares surge 18.00% premarket after exercising put option with PsyLabs and securing strategic equity investment.

Psyence Biomedical Ltd. (PBM) surged 18% in premarket trading following its announcement that PsyLabs exercised a put option and secured a strategic equity investment. The move strengthens supply chain security and advances commercialization pathways for the company’s psychedelic therapy products. This development aligns with recent operational milestones, including high-purity ibogaine production and a debt-free balance sheet with $12 million in cash, reinforcing investor confidence in its long-term growth strategy. The premarket rally reflects optimism over the partnership’s potential to accelerate clinical trials and market expansion.